AvenCell Therapeutics

Coming – December 15

The breakthrough That Makes CAR-T Therapy Truly Scalable

Date and Time

December 15

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies, off-the-shelf cell therapies made from healthy donor cells that perform as well or better than a patient’s own.

Traditional CAR-T therapies have transformed outcomes for some patients but remain limited by high cost, long manufacturing times, and patient-specific production. AvenCell’s proprietary gene-editing and switchable receptor technologies overcome these barriers, enabling scalable, stockpiled, and more potent treatments at a fraction of current costs. The company’s two lead programs target billion-dollar markets.

With a $40 million non-dilutive grant from Japan’s AMED agency and strong backing from Blackstone Life Sciences, Novo Holdings, and F-Prime Capital, AvenCell is well positioned to deliver multiple near-term value inflection points and potential strategic exits.

Please join our webinar with AvenCell CEO, Andrew Schiermeier, to hear how their unique allogenic CAR-T Platform has the potential to transform the lives of patients with hard to treat cancers

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.